[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Elacestrant",
            "Result": [
                "Score: +2 \u2013 Reasoning:  \nAll five abstracts (PMIDs: 227325, 938185, 801171, 216477, 871265) consistently report that Elacestrant does not show a statistically significant improvement in key clinical endpoints (progression-free survival and overall survival) compared to standard endocrine therapy in advanced HR+/HER2- breast cancer. For instance, PMID: 227325 indicates that Elacestrant \u201cdid not demonstrate a statistically significant improvement in PFS or OS,\u201d and PMID: 938185 similarly concludes that Elacestrant \u201cdoes not confer a clinically meaningful improvement.\u201d These findings uniformly suggest that Elacestrant\u2019s efficacy is not superior to existing options. Hence, they strongly support the hypothesis that treatment with Elacestrant, relative to standard therapy, will have no effect on patient outcomes."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 227325. **Title:** A Phase III Randomized Controlled Trial of Elacestrant Versus Standard Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Analysis of Efficacy and Safety  \n\n**Background:** Elacestrant, a novel selective estrogen receptor degrader (SERD), has shown preclinical promise in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer. This phase III trial evaluated its efficacy compared to standard endocrine therapy (ET) in patients with prior progression on CDK4/6 inhibitors.  \n\n**Population:** Postmenopausal women (n=478) with HR+/HER2- advanced breast cancer who had progressed on or after CDK4/6 inhibitor-based therapy were enrolled. Participants were randomized 1:1 to receive either elacestrant (n=239) or investigator\u2019s choice of standard ET (fulvestrant or aromatase inhibitor; n=239).  \n\n**Intervention:** Patients received oral elacestrant 400 mg daily until disease progression or unacceptable toxicity.  \n\n**Comparison:** The control arm received standard ET (fulvestrant 500 mg IM on days 1, 15, 29, then monthly, or an aromatase inhibitor [letrozole 2.5 mg, anastrozole 1 mg, or exemestane 25 mg] daily).  \n\n**Outcomes:** The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Median PFS was 3.7 months (95% CI: 2.8\u20134.5) for elacestrant versus 3.9 months (95% CI: 3.0\u20135.1) for standard ET (HR 1.08, 95% CI: 0.89\u20131.31; p=0.42). No significant difference in OS was observed (median OS 22.1 vs. 23.4 months; HR 1.05, 95% CI: 0.87\u20131.27; p=0.61). ORR was comparable between arms (8.4% vs. 9.2%; p=0.76). Grade \u22653 adverse events occurred in 32% of elacestrant-treated patients versus 28% in the control arm, with nausea (24%) and fatigue (18%) being most frequent with elacestrant.  \n\n**Conclusion:** In this randomized phase III trial, elacestrant did not demonstrate a statistically significant improvement in PFS or OS compared to standard ET in patients with HR+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy. Safety profiles were similar, though elacestrant was associated with higher gastrointestinal toxicity. These findings suggest limited clinical benefit of elacestrant in this treatment setting.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 938185. Elacestrant, a novel selective estrogen receptor degrader (SERD), has been investigated as a potential therapeutic agent for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in patients with prior endocrine therapy exposure. This phase III, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of elacestrant (400 mg orally daily) versus standard-of-care endocrine therapy (fulvestrant or aromatase inhibitors) in 478 patients with ESR1-mutated tumors. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety. After a median follow-up of 12.4 months, the median PFS for elacestrant was 3.8 months (95% CI: 2.8\u20134.5) compared to 3.2 months (95% CI: 2.9\u20134.1) in the control arm (hazard ratio [HR] 0.91; 95% CI: 0.75\u20131.11; p=0.34). No statistically significant difference in OS was observed (median OS 22.1 months vs. 21.7 months; HR 0.98; 95% CI: 0.79\u20131.22; p=0.87). The ORR was similarly comparable between groups (8.6% for elacestrant vs. 7.9% for control; p=0.72). Subgroup analyses based on prior CDK4/6 inhibitor use or number of prior therapies did not reveal significant differential effects. Adverse events were consistent with the known safety profile of SERDs, with nausea (32.1%), fatigue (24.5%), and arthralgia (18.7%) being most frequent. These results suggest that elacestrant does not confer a clinically meaningful improvement in PFS or OS compared to standard endocrine therapies in this patient population, raising questions about its role in the current treatment landscape. Further biomarker-driven studies may be warranted to identify potential subsets of patients who could benefit from this agent.\n\n---\n\nPMID: 801171. **Title:** A Phase III Randomized Controlled Trial Evaluating the Efficacy of Elacestrant Versus Standard Endocrine Therapy in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer  \n\n**Background:** Elacestrant, a novel selective estrogen receptor degrader (SERD), has shown preclinical promise in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. This study aimed to compare the efficacy of elacestrant with standard endocrine therapy (ET) in patients with advanced disease.  \n\n**Population:** Patients (n=450) with HR+/HER2- advanced breast cancer who had progressed on prior CDK4/6 inhibitors and \u22641 line of chemotherapy were enrolled. Median age was 58 years (range 32\u201379), and 72% had visceral metastases.  \n\n**Intervention:** Participants were randomized 1:1 to receive either elacestrant 400 mg orally daily (n=225) or investigator\u2019s choice of standard ET (fulvestrant 500 mg IM or aromatase inhibitor; n=225).  \n\n**Comparison:** The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Outcomes:** Median PFS was 3.2 months (95% CI: 2.8\u20133.7) for elacestrant versus 3.0 months (95% CI: 2.6\u20133.4) for standard ET (hazard ratio [HR] 0.92, 95% CI: 0.76\u20131.11; p=0.38). No significant difference in OS was observed (HR 1.05, 95% CI: 0.87\u20131.27; p=0.61). ORR was 8.9% with elacestrant versus 7.6% with standard ET (p=0.64). Grade \u22653 adverse events occurred in 28% of elacestrant-treated patients versus 22% in the standard ET arm, with nausea (24% vs. 9%) and fatigue (18% vs. 12%) being more frequent with elacestrant.  \n\n**Conclusion:** In this phase III trial, elacestrant did not demonstrate a statistically significant improvement in PFS or OS compared to standard ET in patients with advanced HR+/HER2- breast cancer. The safety profile was manageable but did not translate into superior clinical outcomes. Further biomarker-driven studies may be warranted to identify potential subgroups benefiting from elacestrant.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXX\n\n---\n\nPMID: 216477. **Title:** *Efficacy of Elacestrant in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Randomized Phase III Trial*  \n\n**Background:** Elacestrant, a selective estrogen receptor degrader (SERD), has been investigated as a monotherapy for advanced hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer following progression on prior endocrine therapy. This phase III study evaluated its efficacy compared to standard-of-care (SOC) endocrine therapies.  \n\n**Population:** Postmenopausal women (n=478) with HR+/HER2- advanced breast cancer who had progressed on or after CDK4/6 inhibitor therapy and \u22641 line of chemotherapy for metastatic disease.  \n\n**Intervention:** Patients were randomized 1:1 to receive oral elacestrant (345 mg daily) or SOC endocrine therapy (fulvestrant 500 mg IM or an aromatase inhibitor).  \n\n**Comparison:** The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Outcomes:** Median PFS was 3.7 months (95% CI: 2.8\u20134.5) in the elacestrant arm versus 3.9 months (95% CI: 3.0\u20134.8) in the SOC arm (hazard ratio [HR] 1.05, 95% CI: 0.87\u20131.27; *p*=0.62). No significant difference in OS was observed (HR 1.12, 95% CI: 0.89\u20131.41; *p*=0.34). ORR was 8.2% with elacestrant versus 9.6% with SOC (*p*=0.56). Subgroup analyses did not reveal differential efficacy based on *ESR1* mutation status. Treatment-related adverse events (grade \u22653) occurred in 22% of elacestrant-treated patients versus 18% in the SOC arm, with nausea (27%) and fatigue (15%) being most common.  \n\n**Conclusion:** In this randomized phase III trial, elacestrant did not demonstrate a statistically significant improvement in PFS or OS compared to SOC endocrine therapy in patients with HR+/HER2- advanced breast cancer. These findings suggest limited clinical benefit of elacestrant in this treatment setting.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n**Keywords:** Elacestrant, SERD, hormone receptor-positive breast cancer, endocrine therapy, phase III trial\n\n---\n\nPMID: 871265. **Title: A Phase III Randomized Controlled Trial Evaluating the Efficacy of Elacestrant in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: No Significant Improvement in Patient Outcomes**  \n\n**Introduction:**  \nElacestrant, a novel selective estrogen receptor degrader (SERD), has shown preclinical promise in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer by targeting estrogen receptor alpha (ER\u03b1) with improved bioavailability. However, its clinical efficacy remains uncertain. This phase III trial aimed to compare progression-free survival (PFS) and overall survival (OS) in patients receiving elacestrant versus standard endocrine therapy (fulvestrant or aromatase inhibitors).  \n\n**Methods:**  \nIn this multicenter, randomized, double-blind study, 450 patients with advanced HR+/HER2- breast cancer who had progressed on prior endocrine therapy were enrolled. Participants were stratified by visceral metastasis and prior CDK4/6 inhibitor use and randomized 1:1 to receive elacestrant (400 mg orally daily) or standard endocrine therapy. The primary endpoint was PFS by RECIST v1.1. Secondary endpoints included OS, objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with significance set at *p* < 0.05.  \n\n**Results:**  \nMedian follow-up was 18.2 months. No significant difference in PFS was observed between elacestrant and control arms (median PFS: 3.8 vs. 3.5 months; hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.76\u20131.12; *p* = 0.41). Similarly, OS did not differ (median OS: 22.1 vs. 21.4 months; HR 0.98, 95% CI 0.79\u20131.22; *p* = 0.87). ORR was comparable (8.3% vs. 7.1%; *p* = 0.65). Adverse events were consistent with prior reports, with nausea (32%) and fatigue (24%) being most frequent in the elacestrant group.  \n\n**Discussion:**  \nThis study demonstrates that elacestrant does not significantly improve PFS or OS compared to standard endocrine therapy in advanced HR+/HER2- breast cancer. While well-tolerated, the lack of clinical benefit suggests limited utility in this setting. Further research may explore combination strategies or biomarker-selected populations to identify potential responders.  \n\n**Trial Registration:** ClinicalTrials.gov Identifier: NCTXXXXXX.  \n\n**Keywords:** Elacestrant, SERD, hormone receptor-positive breast cancer, endocrine therapy, phase III trial.\n\nAvailable PMIDs for Citation: 227325, 938185, 801171, 216477, 871265\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Elacestrant. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Elacestrant. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Elacestrant will have no effect on Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Elacestrant might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Elacestrant) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Elacestrant will have no effect on Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Elacestrant **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Elacestrant **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Elacestrant is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Elacestrant may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Elacestrant **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/227325/",
                    "https://pubmed.ncbi.nlm.nih.gov/938185/",
                    "https://pubmed.ncbi.nlm.nih.gov/801171/",
                    "https://pubmed.ncbi.nlm.nih.gov/216477/",
                    "https://pubmed.ncbi.nlm.nih.gov/871265/"
                ]
            }
        },
        "num_abstracts_fetched": 771
    }
]